Endocrine Abstracts

Anaplastic thyroid cancer (ATC) is the most aggressive thyroid cancer with a median survival of about 6 months. So far, no therapies offering a survival benefit are established. Thus, new therapeutic approaches are urgently needed. In general, genetic alterations leading to ATC increase PI3K and MAPK/ERK signaling and include mutations in receptor tyrosine kinases and tumor suppressor genes. They often occur together with the loss of P53, the most prevalent mutation in human A...

Anaplastic thyroid carcinoma (ATC) is a rare and aggressive malignancy with only limited effective systemic treatment options. The identification of actionable genetic lesions and its exploitation has expanded therapeutic approaches and especially for the subset of BRAFV600E mutated ATC (11-25%) combined BRAF- and MEK-inhibition indicated meaningful activity. Still, further effective therapeutic options are required for patients without identifiable driver mutations. The role ...

Therapeutic strategy for the management of radioiodine-refractory differentiated thyroid cancer (rrDTC) and advanced medullary thyroid cancer (MTC) had changed with the introduction of the multityrosine-kinase-inhibitors (MKI) sorafenib&lenvatinib and vandetanib&cabozantinib respectively. Only recently, the market approval of pralsetinib (FDA) and selpercatinib (FDA and EMA) as first highly selective RET(rearranged during transfection)- inhibitors have expande...